Pri-Mir-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: A case-control study

Medicine (United States)

Volumn 94, Issue 38, 2015, Pages

  Chen, Peng ^a,b   Sun, Ruifen ^b,c   Pu, Yan ^a   Bai, Peng ^a   Yuan, Fang ^b   Liang, Yundan ^b   Zhou, Bin ^b   Wang, Yanyun ^b   Sun, Yinghe ^d   Zhu, Jingqiang ^d   Zhang, Lin ^a,b   Gao, Linbo ^b  

^a SICHUAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c YUNNAN UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 34B; PROTEIN P53; UNCLASSIFIED DRUG; MIRN34 MICRORNA, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CARCINOMA; CARCINOMA; CHINA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADULT; CARCINOMA; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942525117     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001536     Document Type: Article

References (43)

1. Trovisco V, Soares P, Preto A, et al. Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endocrinol Metabol. 2007;51:643-653.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer. 2003;103:105-109.
4. Fallah M, Pukkala E, Tryggvadottir L, et al. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries. J Med Genet. 2013;50:373-382.
5. Adjadj E, Schlumberger M, de Vathaire F. Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol. 2009;10:181-190.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
7. Moreno-Moya JM, Vilella F, Simon C. MicroRNA: key gene expression regulators. Fertil Steril. 2014;101:1516-1523.
8. Cheng AM, Byrom MW, Shelton J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33:1290-1297.
9. Tili E, Michaille JJ, Calin GA. Expression and function of micro-RNAs in immune cells during normal or disease state. Int J Med Sci. 2008;5:73-79.
10. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999-3004.
11. Li X, Abdel-Mageed AB, Mondal D, et al. MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med. 2013;6:74-80.
12. Yip L, Kelly L, Shuai Y, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18:2035-2041.
13. Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development (Cambridge, England). 1998;125:4909-4917.
14. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222:42-49.
15. Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128:412-417.
16. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130-1134.
17. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298-1307.
18. Botchkarev VA. Flores ER. p53/p63/p73 in the epidermis in health and disease. Cold Spring Harbor Perspect Med. 2014:4.
19. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229-234.
20. Dumont P, Leu JI, Della Pietra AC 3rd et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357-365.
21. Boltze C, Roessner A, Landt O, et al. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol. 2002;21:1151-1154.
22. Granja F, Morari J, Morari EC, et al. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 2004;210:151-157.
23. Rogounovitch TI, Saenko VA, Ashizawa K, et al. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. Oncol Rep. 2006;15:949-956.
24. Wu B, Guo D, Guo Y. Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis. Tumour Biol. 2014;35:561-565.
25. Pan XM, Sun RF, Li ZH, et al. Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomark. 2015;19:198-202.
26. Li L, Wu J, Sima X, et al. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol. 2013;34:1919-1923.
27. Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394:415-420.
28. Siprashvili Z, Webster DE, Kretz M, et al. Identification of proteins binding coding and non-coding human RNAs using protein microarrays. BMC Genom. 2012;13:633.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
30. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
31. Suzuki H, Yamamoto E, Nojima M, et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010;31:2066-2073.
32. Sole X, Guino E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics (Oxford, England). 2006;22: 1928-1929.
33. Hagman Z, Larne O, Edsjo A, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. International journal of cancer. J Int Cancer. 2010;127:2768-2776.
34. Tsai KW, Wu CW, Hu LY, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. International journal of cancer. J Int Cancer. 2011;129:2600-2610.
35. Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68:4123-4132.
36. Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of primiR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524:156-160.
37. Zhang S, Qian J, Cao Q, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 2014;29: 149-154.
38. Tian Q, Jia J, Ling S, et al. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol. 2014;40:67-72.
39. Zhang J, Huang X, Xiao J, et al. Pri-miR-124 rs531564 and primiR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PloS One. 2014;9:e100055.
40. Yin J, Wang X, Zheng L, et al. Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One. 2013;8:e80570.
41. Yi DH, Wang BG, Zhong XP, et al. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data. Tumour Biol. 2014;35:11967-11975.
42. Morita N, Ikeda Y, Takami H. Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg. 2008;32:2617-2622.
43. Cheng CY, Hwang CI, Corney DC, et al. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 2014;6:1000-1007.